| 1 |
33693561 | Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. | 2022 Jan 7 |
1 |
| 2 |
33795598 | Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults. | 2022 Feb 1 |
1 |
| 3 |
34074166 | Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report. | 2022 Jan |
1 |
| 4 |
34097573 | Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. | 2022 Apr 3 |
1 |
| 5 |
34423448 | Leukocytoclastic vasculitis due to ruxolitinib treatment: A rare adverse effect. | 2022 Apr |
1 |
| 6 |
34521299 | Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). | 2022 Jan |
2 |
| 7 |
34536415 | Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK. | 2022 Apr |
1 |
| 8 |
34655610 | Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling. | 2022 Apr |
1 |
| 9 |
34694880 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults. | 2022 Jan 18 |
1 |
| 10 |
35131254 | Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study. | 2022 Feb 5 |
1 |
| 11 |
35131544 | Propionate induces cross-tolerance to TLR1/2 and TLR4 agonists in an IFIT-dependent manner. | 2022 Mar |
1 |
| 12 |
35186752 | FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma. | 2022 |
1 |
| 13 |
35266648 | Interferon-gamma induces melanogenesis via post-translational regulation of tyrosinase. | 2022 May |
1 |
| 14 |
35337171 | New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib. | 2022 Mar 19 |
1 |
| 15 |
35363892 | Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. | 2022 Jul 1 |
2 |
| 16 |
35368221 | A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis. | 2022 May |
2 |
| 17 |
35368384 | Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2022 May |
2 |
| 18 |
35371054 | Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. | 2022 |
3 |
| 19 |
35382859 | Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2. | 2022 Apr 5 |
1 |
| 20 |
35437311 | Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. | 2022 Jun |
1 |
| 21 |
35443042 | Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. | 2022 Apr 20 |
1 |
| 22 |
35507130 | Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations. | 2022 May 4 |
1 |
| 23 |
35595725 | GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. | 2022 May 20 |
1 |
| 24 |
35597252 | Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. | 2022 May 18 |
1 |
| 25 |
35604239 | Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report. | 2022 Jun 9 |
1 |
| 26 |
35635540 | Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis. | 2022 Jun 16 |
2 |
| 27 |
32201152 | Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review. | 2021 Sep |
1 |
| 28 |
32732367 | A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis. | 2021 Jul 1 |
1 |
| 29 |
32814839 | Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. | 2021 Apr |
2 |
| 30 |
32981124 | Efficacy and feasibility of ruxolitinib in chronic steroid-refractory GVHD in a pediatric intestine transplant. | 2021 May |
1 |
| 31 |
33129109 | Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. | 2021 Jan |
1 |
| 32 |
33222197 | Second primary malignancy in myelofibrosis patients treated with ruxolitinib. | 2021 Apr |
2 |
| 33 |
33338537 | JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. | 2021 Jun |
1 |
| 34 |
33465556 | Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. | 2021 Feb |
1 |
| 35 |
33502484 | Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. | 2021 Jan 4 |
1 |
| 36 |
33509955 | Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease. | 2021 Aug |
1 |
| 37 |
33517393 | Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. | 2021 Apr 26 |
1 |
| 38 |
33523540 | Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. | 2021 May |
1 |
| 39 |
33534941 | Ruxolitinib inhibits poly(I:C) and type 2 cytokines-induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma. | 2021 Jun |
1 |
| 40 |
33585999 | Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. | 2021 May |
2 |
| 41 |
33598678 | BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. | 2021 Jun 24 |
2 |
| 42 |
33694335 | Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib. | 2021 Jun |
1 |
| 43 |
33747209 | Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. | 2021 May |
3 |
| 44 |
33782031 | Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. | 2021 Jun 15 |
1 |
| 45 |
33792103 | Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. | 2021 May |
1 |
| 46 |
33827897 | SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. | 2021 Apr 7 |
1 |
| 47 |
33830087 | Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. | 2021 Apr 8 |
1 |
| 48 |
33845867 | Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. | 2021 Apr 12 |
2 |
| 49 |
33954282 | Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models. | 2021 May |
1 |
| 50 |
33965175 | Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. | 2021 May |
2 |